CA2338675A1 - Topographie spectrale de matiere d'origine mammalienne - Google Patents
Topographie spectrale de matiere d'origine mammalienne Download PDFInfo
- Publication number
- CA2338675A1 CA2338675A1 CA002338675A CA2338675A CA2338675A1 CA 2338675 A1 CA2338675 A1 CA 2338675A1 CA 002338675 A CA002338675 A CA 002338675A CA 2338675 A CA2338675 A CA 2338675A CA 2338675 A1 CA2338675 A1 CA 2338675A1
- Authority
- CA
- Canada
- Prior art keywords
- image
- matter
- specimen
- slice
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003595 spectral effect Effects 0.000 title claims abstract description 104
- 238000012876 topography Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 91
- 238000013528 artificial neural network Methods 0.000 claims abstract description 31
- 238000012545 processing Methods 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 23
- 238000000701 chemical imaging Methods 0.000 claims abstract description 18
- 230000001575 pathological effect Effects 0.000 claims abstract description 8
- 230000000007 visual effect Effects 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 6
- 238000001228 spectrum Methods 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 230000003287 optical effect Effects 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 238000004611 spectroscopical analysis Methods 0.000 claims description 19
- 230000007170 pathology Effects 0.000 claims description 18
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 17
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 16
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 15
- 238000001574 biopsy Methods 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 238000003384 imaging method Methods 0.000 claims description 11
- 230000000877 morphologic effect Effects 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 5
- 108010014258 Elastin Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229920002549 elastin Polymers 0.000 claims description 5
- 238000010183 spectrum analysis Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 238000003759 clinical diagnosis Methods 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 3
- 238000003125 immunofluorescent labeling Methods 0.000 claims description 3
- 230000002055 immunohistochemical effect Effects 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 230000001744 histochemical effect Effects 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 30
- 208000035475 disorder Diseases 0.000 description 19
- 201000008827 tuberculosis Diseases 0.000 description 18
- 241000701806 Human papillomavirus Species 0.000 description 17
- 238000009595 pap smear Methods 0.000 description 16
- 238000010186 staining Methods 0.000 description 12
- 210000000709 aorta Anatomy 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000386 microscopy Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 6
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004061 bleaching Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 244000007853 Sarothamnus scoparius Species 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000007781 pre-processing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010054122 Myocardial calcification Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- -1 elastin and collagen Chemical class 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- XYITYKDGJLHYPW-UHFFFAOYSA-M sodium 2-iodohippurate Chemical compound [Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1I XYITYKDGJLHYPW-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/2823—Imaging spectrometer
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Image Processing (AREA)
- Spectrometry And Color Measurement (AREA)
Abstract
La présente invention concerne un système et un procédé de topographie multispectrale qui consiste à éclairer une matière d'origine mammalienne (18) au moyen d'une source lumineuse (43) et à transmettre une image d'une coupe (20) de ladite matière à un prisme imageur multispectral et à un spectrographe à miroir (30), lesquels dispersent plus ou moins simultanément la lumière transmise. L'image spectrale ainsi obtenue est préparée en vue d'un traitement ultérieur. Le processeur (37), qui est généralement intégré à un système informatique, traite les données spectrales numériques au moyen d'un réseau neuronal aux fins de diagnostic. La source lumineuse peut être constituée par de la lumière filtrée absorbée par une matière destinée spécifiquement à ré-émettre de la lumière (fluorescence). La matière peut être constituée par des spécimens pathologiques qui doivent être grossis et analysés au microscope (électronique à transmission ou par fluorescence) ou bien se présenter sous sa forme in vivo, auquel cas l'image est transmise par un autre transmetteur classique d'images tel qu'un endoscope. Ce système peut également afficher l'image visuelle transmise ainsi que l'image spectrale dans le cadre du travail de diagnostic.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12287698A | 1998-07-27 | 1998-07-27 | |
| US09/122,876 | 1998-07-27 | ||
| PCT/US1999/017004 WO2000006980A1 (fr) | 1998-07-27 | 1999-07-27 | Topographie spectrale de matiere d'origine mammalienne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2338675A1 true CA2338675A1 (fr) | 2000-02-10 |
Family
ID=22405360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002338675A Abandoned CA2338675A1 (fr) | 1998-07-27 | 1999-07-27 | Topographie spectrale de matiere d'origine mammalienne |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1101083A1 (fr) |
| JP (1) | JP2002521685A (fr) |
| AU (1) | AU5235299A (fr) |
| CA (1) | CA2338675A1 (fr) |
| WO (1) | WO2000006980A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3662271A4 (fr) * | 2017-07-31 | 2021-04-14 | Smiths Detection Inc. | Système de détermination de la présence d'une substance d'intérêt dans un échantillon |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6364829B1 (en) | 1999-01-26 | 2002-04-02 | Newton Laboratories, Inc. | Autofluorescence imaging system for endoscopy |
| AU3349200A (en) | 1999-01-26 | 2000-08-07 | Newton Laboratories, Inc. | Autofluorescence imaging system for endoscopy |
| US6734420B2 (en) * | 2000-04-06 | 2004-05-11 | Quantum Dot Corporation | Differentiable spectral bar code methods and systems |
| JP2004219092A (ja) * | 2003-01-09 | 2004-08-05 | Univ Waseda | リアルタイム分光画像分析装置及び分析方法 |
| DE10304267B9 (de) | 2003-02-03 | 2005-12-15 | Carl Zeiss | Augenchirurgie-Mikroskopiesystem |
| DE102005045961B4 (de) * | 2005-09-26 | 2018-11-15 | Siemens Healthcare Gmbh | Verfahren und Vorrichtung zur Darstellung eines einen Fluoreszenzfarbstoff enthaltenden Gewebes |
| WO2009006696A1 (fr) * | 2007-07-10 | 2009-01-15 | Molecular Discovery Systems | Procédé de pathologie |
| ES2573945T3 (es) * | 2008-09-16 | 2016-06-13 | Novartis Ag | Cuantificación reproducible de expresión de biomarcadores |
| CN102549617B (zh) * | 2009-10-05 | 2014-10-08 | 富士通株式会社 | 生物体信息处理装置、生物体信息处理方法以及生物体信息处理用计算机程序 |
| JP5384453B2 (ja) * | 2010-09-09 | 2014-01-08 | シャープ株式会社 | 測定装置、測定システム、測定方法、制御プログラム、および、記録媒体 |
| JP5766958B2 (ja) * | 2011-01-21 | 2015-08-19 | オリンパス株式会社 | 顕微鏡システム、情報処理装置、及び情報処理プログラム |
| CN102721469B (zh) * | 2012-06-14 | 2015-05-13 | 中国科学院自动化研究所 | 双相机的多光谱成像系统和方法 |
| CN102809429A (zh) * | 2012-07-26 | 2012-12-05 | 中国科学院自动化研究所 | 基于双相机的多光谱成像系统和方法 |
| EP3306307A4 (fr) * | 2015-06-02 | 2019-02-27 | National University Corporation Asahikawa Medical University | Dispositif d'aide à l'observation, procédé de traitement d'informations et programme |
| EP3472595A4 (fr) * | 2016-06-21 | 2020-08-12 | SRI International | Procédés et appareils d'imagerie hyperspectrale |
| CN110573883B (zh) * | 2017-04-13 | 2023-05-30 | 美国西门子医学诊断股份有限公司 | 用于在样本表征期间确定标签计数的方法和装置 |
| EP3614191A1 (fr) * | 2018-08-20 | 2020-02-26 | Till GmbH | Dispositif de microscope |
| GB2600719B (en) * | 2020-11-05 | 2023-10-11 | Oxford Nanoimaging Ltd | Fluorescence assay |
| CN114820502B (zh) * | 2022-04-21 | 2023-10-24 | 济宁医学院附属医院 | 一种用于肠粘膜组织中蛋白激酶ck2的着色检测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5784162A (en) * | 1993-08-18 | 1998-07-21 | Applied Spectral Imaging Ltd. | Spectral bio-imaging methods for biological research, medical diagnostics and therapy |
| US5528368A (en) * | 1992-03-06 | 1996-06-18 | The United States Of America As Represented By The Department Of Health And Human Services | Spectroscopic imaging device employing imaging quality spectral filters |
| US5424827A (en) * | 1993-04-30 | 1995-06-13 | Litton Systems, Inc. | Optical system and method for eliminating overlap of diffraction spectra |
| US5793049A (en) * | 1995-07-06 | 1998-08-11 | Yale University | Optical filtering and spectroscopic imaging |
-
1999
- 1999-07-27 EP EP99937539A patent/EP1101083A1/fr not_active Withdrawn
- 1999-07-27 WO PCT/US1999/017004 patent/WO2000006980A1/fr not_active Application Discontinuation
- 1999-07-27 CA CA002338675A patent/CA2338675A1/fr not_active Abandoned
- 1999-07-27 AU AU52352/99A patent/AU5235299A/en not_active Abandoned
- 1999-07-27 JP JP2000562725A patent/JP2002521685A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3662271A4 (fr) * | 2017-07-31 | 2021-04-14 | Smiths Detection Inc. | Système de détermination de la présence d'une substance d'intérêt dans un échantillon |
| US11379709B2 (en) | 2017-07-31 | 2022-07-05 | Smiths Detection Inc. | System for determining the presence of a substance of interest in a sample |
| US11769039B2 (en) | 2017-07-31 | 2023-09-26 | Smiths Detection, Inc. | System for determining the presence of a substance of interest in a sample |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1101083A1 (fr) | 2001-05-23 |
| JP2002521685A (ja) | 2002-07-16 |
| WO2000006980A1 (fr) | 2000-02-10 |
| AU5235299A (en) | 2000-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2338675A1 (fr) | Topographie spectrale de matiere d'origine mammalienne | |
| US6337472B1 (en) | Light imaging microscope having spatially resolved images | |
| US8290236B2 (en) | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots | |
| US6690817B1 (en) | Spectral bio-imaging data for cell classification using internal reference | |
| US6181414B1 (en) | Infrared spectroscopy for medical imaging | |
| US7570356B2 (en) | System and method for classifying cells and the pharmaceutical treatment of such cells using Raman spectroscopy | |
| US6246785B1 (en) | Automated, microscope-assisted examination process of tissue or bodily fluid samples | |
| EP1065496A2 (fr) | Procédé et dispositif pour l'extraction d'images séparées à partir d'une pluralité de chromogènes dans un échantillon biologique | |
| WO1998043042A9 (fr) | Procedes de bio-imagerie spectrale pour la classification de cellules | |
| US20100093015A1 (en) | Spectroscopic systems and methods for classifying and pharmaceutically treating cells | |
| US7316904B1 (en) | Automated pap screening using optical detection of HPV with or without multispectral imaging | |
| De Jong et al. | Raman spectroscopic detection of changes in molecular composition of bladder muscle tissue caused by outlet obstruction | |
| WO2000010451A1 (fr) | Systeme et procede de topographie spectrale de substances provenant de mammiferes, utilisant une illumination par lumiere blanche | |
| Vari et al. | Telepathology and imaging spectroscopy as a new modality in histopathology | |
| Lerner et al. | Spectral topography of histopathological samples | |
| CA2279945A1 (fr) | Spectroscopie infrarouge pour l'imagerie medicale | |
| CA2858931C (fr) | Procede d'analyse d'un echantillon biologique, et dispositif mettant en oeuvre ce procede | |
| WO2023157756A1 (fr) | Dispositif de traitement d'informations, système d'analyse d'échantillon biologique et procédé d'analyse d'échantillon biologique | |
| Tsurui et al. | Hyperspectral imaging of pathology samples | |
| LERNER | Telepathology and Imaging Spectroscopy as a New Modality in Histopathology | |
| Lerner | Spectral imaging with a prism-based spectrometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |